St. Johns Investment Management Company LLC Has $1.22 Million Position in Johnson & Johnson $JNJ

St. Johns Investment Management Company LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 5.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 7,998 shares of the company’s stock after selling 490 shares during the quarter. St. Johns Investment Management Company LLC’s holdings in Johnson & Johnson were worth $1,222,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. GFG Capital LLC acquired a new position in Johnson & Johnson in the second quarter worth $35,000. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson during the first quarter valued at $47,000. 1248 Management LLC acquired a new position in shares of Johnson & Johnson during the first quarter valued at $48,000. von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson during the first quarter valued at $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Johnson & Johnson during the first quarter valued at $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.5%

Shares of Johnson & Johnson stock opened at $192.81 on Thursday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market capitalization of $464.35 billion, a P/E ratio of 18.61, a price-to-earnings-growth ratio of 2.25 and a beta of 0.40. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.48. The business has a 50-day moving average of $181.64 and a two-hundred day moving average of $165.56.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. As a group, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on JNJ shares. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. UBS Group upped their price target on Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research note on Tuesday, October 14th. Citigroup upped their price target on Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, October 15th. Sanford C. Bernstein raised their target price on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a report on Monday, October 6th. Finally, HSBC increased their price target on Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Thursday, October 16th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $199.05.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.